Please login to the form below

Not currently logged in
Email:
Password:

Bayer appoints president of Americas pharma business

Dr Carsten Brunn to lead operations across the US, Canada, Central and Latin America

Bayer Dr Carsten BrunnBayer has appointed Dr Carsten Brunn as the president of its pharmaceuticals business in the Americas, overseeing the company's operations in the US, Canada and Central and Latin America.

Dr Brunn first joined Bayer in 2011 as global head of primary care, based in Beijing, China, and has subsequently served as head of Bayer's pharmaceuticals commercial operations in Japan since 2013.

Prior to this, Dr Brunn was vice president of pharma, Asia-Pacific at Bausch & Lomb and served as global head of marketing at Basilea Pharmaceutica International, based in Basel, Switzerland.

He also brings branding and sales leadership experience from Novartis and Eli Lilly, and recently served as chairman of European Federation of Pharmaceutical Industries and Associations (EFPIA), Japan.

Dieter Weinand, president of Bayer's pharmaceutical division, said: “Carsten is a strategic and highly respected leader in the pharmaceutical industry and I'm delighted to have him lead the company's largest pharmaceutical business worldwide.

“Carsten's global perspective and proven track record of successful operational executive at the local level will be a critical asset to us as we continue to build on our current momentum in the US and across the Americas region.”

26th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...

Infographics